AU2021213403B2 - Anti-αvβ8 integrin antibodies for use in treating kidney disease - Google Patents

Anti-αvβ8 integrin antibodies for use in treating kidney disease Download PDF

Info

Publication number
AU2021213403B2
AU2021213403B2 AU2021213403A AU2021213403A AU2021213403B2 AU 2021213403 B2 AU2021213403 B2 AU 2021213403B2 AU 2021213403 A AU2021213403 A AU 2021213403A AU 2021213403 A AU2021213403 A AU 2021213403A AU 2021213403 B2 AU2021213403 B2 AU 2021213403B2
Authority
AU
Australia
Prior art keywords
avp8
integrin
kidney
antibody
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2021213403A
Other languages
English (en)
Other versions
AU2021213403A1 (en
Inventor
David James Baker
Stephanie Claire Heasman
Maria Marcela Herrera
Elena LIARTE MARIN
Carol Patricia Moreno-Quinn
Lynne Anne Murray
Ping Tsui
Yanli Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Original Assignee
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune Ltd filed Critical MedImmune Ltd
Publication of AU2021213403A1 publication Critical patent/AU2021213403A1/en
Application granted granted Critical
Publication of AU2021213403B2 publication Critical patent/AU2021213403B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2021213403A 2020-01-27 2021-01-26 Anti-αvβ8 integrin antibodies for use in treating kidney disease Active AU2021213403B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062966258P 2020-01-27 2020-01-27
US62/966,258 2020-01-27
PCT/EP2021/051753 WO2021151889A1 (en) 2020-01-27 2021-01-26 ANTI-αVβ8 INTEGRIN ANTIBODIES FOR USE IN TREATING KIDNEY DISEASE

Publications (2)

Publication Number Publication Date
AU2021213403A1 AU2021213403A1 (en) 2022-09-15
AU2021213403B2 true AU2021213403B2 (en) 2025-04-10

Family

ID=74561850

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021213403A Active AU2021213403B2 (en) 2020-01-27 2021-01-26 Anti-αvβ8 integrin antibodies for use in treating kidney disease

Country Status (18)

Country Link
US (1) US20230112035A1 (https=)
EP (1) EP4096785A1 (https=)
JP (1) JP7706458B2 (https=)
KR (1) KR20220132567A (https=)
CN (1) CN115151305A (https=)
AR (1) AR121193A1 (https=)
AU (1) AU2021213403B2 (https=)
BR (1) BR112022014633A2 (https=)
CA (1) CA3167390A1 (https=)
CL (1) CL2022001999A1 (https=)
CO (1) CO2022011661A2 (https=)
CR (1) CR20220392A (https=)
EC (1) ECSP22066085A (https=)
IL (1) IL294814A (https=)
MX (1) MX2022009165A (https=)
PH (1) PH12022551863A1 (https=)
TW (1) TWI854088B (https=)
WO (1) WO2021151889A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11359024B2 (en) 2018-09-07 2022-06-14 Pfizer Inc. Anti-AVB8 antibodies and compositions and uses thereof
US20260035468A1 (en) 2022-09-12 2026-02-05 Institut National de la Santé et de la Recherche Médicale New anti-itgb8 antibodies and its uses thereof
TW202446789A (zh) * 2023-03-31 2024-12-01 美商建南德克公司 抗αｖβ８整合素抗體及使用方法
CN117143241B (zh) * 2023-10-26 2024-02-23 迈威(上海)生物科技股份有限公司 与人整合素蛋白itgav/itgb8特异性结合的单克隆抗体
CN117126282B (zh) * 2023-10-26 2024-01-12 迈威(上海)生物科技股份有限公司 抗体及其在制备阻断αvβ8与Latent TGF-β的结合的药物中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011103490A2 (en) * 2010-02-18 2011-08-25 The Regents Of The University Of California INTEGRIN αVβ8 NEUTRALIZING ANTIBODY
WO2013026004A2 (en) * 2011-08-17 2013-02-21 The Regents Of The University Of California Antibodies that bind integrin alpha-v beta-8
WO2015195835A2 (en) * 2014-06-17 2015-12-23 The Regents Of The University Of California Improved alpha-v beta-8 antibodies
WO2018227018A1 (en) * 2017-06-07 2018-12-13 Silverback Therapeutics, Inc. Antibody conjugates of immune-modulatory compounds and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US20170073406A1 (en) * 2014-05-06 2017-03-16 Scholar Rock, Inc. Compositions and methods for growth factor modulation
CA3112523A1 (en) * 2018-08-08 2020-02-13 The General Hospital Corporation Integrin antagonists

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011103490A2 (en) * 2010-02-18 2011-08-25 The Regents Of The University Of California INTEGRIN αVβ8 NEUTRALIZING ANTIBODY
WO2013026004A2 (en) * 2011-08-17 2013-02-21 The Regents Of The University Of California Antibodies that bind integrin alpha-v beta-8
WO2015195835A2 (en) * 2014-06-17 2015-12-23 The Regents Of The University Of California Improved alpha-v beta-8 antibodies
WO2018227018A1 (en) * 2017-06-07 2018-12-13 Silverback Therapeutics, Inc. Antibody conjugates of immune-modulatory compounds and uses thereof

Also Published As

Publication number Publication date
CR20220392A (es) 2022-09-07
JP7706458B2 (ja) 2025-07-11
CO2022011661A2 (es) 2022-08-30
CN115151305A (zh) 2022-10-04
TW202140554A (zh) 2021-11-01
JP2023511686A (ja) 2023-03-22
PH12022551863A1 (en) 2024-01-03
WO2021151889A1 (en) 2021-08-05
TWI854088B (zh) 2024-09-01
KR20220132567A (ko) 2022-09-30
ECSP22066085A (es) 2022-09-30
CA3167390A1 (en) 2021-08-05
MX2022009165A (es) 2022-08-16
EP4096785A1 (en) 2022-12-07
AU2021213403A1 (en) 2022-09-15
BR112022014633A2 (pt) 2022-09-13
AR121193A1 (es) 2022-04-27
IL294814A (en) 2022-09-01
CL2022001999A1 (es) 2023-01-27
US20230112035A1 (en) 2023-04-13

Similar Documents

Publication Publication Date Title
AU2021213403B2 (en) Anti-αvβ8 integrin antibodies for use in treating kidney disease
AU2018272311B2 (en) Anti-CD47 x anti-mesothelin antibodies and methods of use thereof
US10202454B2 (en) Anti-PD-L1 monoclonal antibodies and fragments thereof
US10077305B2 (en) Antibodies against PD-1 and uses thereof
EP2167542B1 (en) Neutralizing monoclonal antibody against human dll4
KR101869413B1 (ko) Ｓ100ａ4 항체들 및 이들의 치료 용도
CN111629754A (zh) 不引起显著红血细胞凝集的抗cd47抗体
NO334834B1 (no) Anti-alfavbeta6-antistoff, celle som produserer slikt antistoff, samt anvendelse av antistoffet for fremstilling av medikamenter
US12258409B2 (en) Method of assessing the efficacy of a test agent for modulating programmed death 1 (PD-1) signaling by using anti-phosphotyrosinylated PD-1 monoclonal antibodies
EP2841457B1 (en) Anti-robo4-antibody
DK2654781T3 (en) Anti-P-selectin antibodies and methods for their use and identification
KR20230029611A (ko) T 세포를 선택적으로 조절하기 위한 이중특이적 분자
US11542329B2 (en) Antibodies targeting Glycoprotein VI
TW201946658A (zh) 抗ｇｉｔｒ抗體及其用途
WO2023145844A1 (ja) 抗ヒトｃｘｃｌ１抗体
JP2022169737A (ja) 抗ｒａｍｐ２抗体
EA049172B1 (ru) АНТИТЕЛА К ИНТЕГРИНУ αvβ8 ДЛЯ ПРИМЕНЕНИЯ ПРИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ ПОЧЕК
KR20230135627A (ko) 항-PDGF-b 항체 및 폐동맥 고혈압 (PAH)을 치료하기 위한 사용 방법
WO2026078647A1 (en) Combination of trispecific antibody targeting bcma, gprc5d and cd3, and pomalidomide for the treatment of multiple myeloma
HK1207093B (en) Anti-robo4-antibody

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)